Xiaowen Zhou

Zhengzhou, 450001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

D-peptide-nanodrug conjugates synergize VISTA blockade and innate activation for cancer immunotherapy.

D-peptide-nanodrug conjugates synergize VISTA blockade and innate activation for cancer immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: March 30, 2026

Enhancing tumor immunotherapy with smart nanoparticles for reprogramming macrophages and blocking the CD47/Sirpα pathway.

Enhancing tumor immunotherapy with smart nanoparticles for reprogramming macrophages and blocking the CD47/Sirpα pathway.

Journal: Materials today. Bio

Published: March 20, 2025

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy.

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy.

Journal: BMC biology

Published: May 08, 2024

Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy.

Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy.

Journal: Biochemical pharmacology

Published: January 21, 2024

Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy.

Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy.

Journal: Acta pharmaceutica Sinica. B

Published: September 24, 2023

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.

Journal: Cell communication and signaling : CCS

Published: August 21, 2023

Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy.

Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy.

Journal: Science China. Life sciences

Published: August 13, 2023

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy.

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy.

Journal: Acta pharmaceutica Sinica. B

Published: March 31, 2023

Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy.

Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy.

Journal: Biochemical pharmacology

Published: March 27, 2023

Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression.

Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression.

Journal: Journal for immunotherapy of cancer

Published: October 10, 2022

Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway.

Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 01, 2021

Dysfunction of the energy sensor NFE2L1 triggers uncontrollable AMPK signaling and glucose metabolism reprogramming.

Dysfunction of the energy sensor NFE2L1 triggers uncontrollable AMPK signaling and glucose metabolism reprogramming.

Journal: Cell death & disease

Published: October 15, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026